Abstract Details
Activity Number:
|
435
|
Type:
|
Contributed
|
Date/Time:
|
Tuesday, August 11, 2015 : 2:00 PM to 3:50 PM
|
Sponsor:
|
Biopharmaceutical Section
|
Abstract #315744
|
View Presentation
|
Title:
|
Improving the Operational Efficiency of Phase II and III Trials
|
Author(s):
|
Jitendra Ganju*
|
Companies:
|
Hyperion Therapeutics
|
Keywords:
|
alpha spending ;
unblinding ;
trial efficiency ;
DSMB
|
Abstract:
|
The period toward the end of patients' participation in late stage clinical trials is highly resource intensive for sponsor. If the trial is a success, the sponsor has to implement the next steps which might be filing for approval of the drug with the US Food and Drug Administration (FDA). To shorten the time interval between trial completion and submission of the package to the FDA, sponsors usually front-load as much work as is possible at risk. The approach is inefficient if the trial fails as the sponsor is unlikely to proceed with the plan that assumed success. This note addresses how to improve the operational efficiency and reduce the risk of work done upfront by letting an independent entity provide the sponsor highly limited but necessary information at an earlier time.
|
Authors who are presenting talks have a * after their name.
Back to the full JSM 2015 program
|
For program information, contact the JSM Registration Department or phone (888) 231-3473.
For Professional Development information, contact the Education Department.
The views expressed here are those of the individual authors and not necessarily those of the JSM sponsors, their officers, or their staff.
2015 JSM Online Program Home
ASA Meetings Department
732 North Washington Street, Alexandria, VA 22314
(703) 684-1221 • meetings@amstat.org
Copyright © American Statistical Association.